10/17/13 Kanzius Cancer Research Foundation announces the latest research advancements from Houston with plans to approach the FDA in early 2014 and begin human trials using the Kanzius Noninvasive Radiowave Cancer Treatment in early 2015.
“Since its inception, the mission of the Kanzius Foundation has been to raise both awareness and funds for research of the innovative, noninvasive cancer treatment created by the late John Kanzius,” began Executive Director, Mark A. Neidig, Sr. “This invention, known as the Kanzius Noninvasive Radiowave Cancer Treatment, has been groundbreaking and we are extremely excited about the progress the research team has made.”
Success in preliminary studies has paved the way for the arrival of the GenV Kanzius Device, which has led to large animal studies with the human-sized Kanzius radiofrequency (RF) field device. Dr. Steven Curley, lead investigator for the Kanzius Project, began research on a controlled group of the large non-human laboratory subjects (pigs) earlier this year. Following the completion of an extensive series of studies, outcomes have been promising. “Essentially what we have found is that we can go to very powerful fields. It does not cause heating of normal tissues; it doesn’t cause damage to normal tissues,” described Curley. “Test subjects are having no side effects or toxic effects from the RF treatment.”
“This is the news we have been waiting for,” exclaimed Neidig, “the world is waiting for the verdict and our researchers say ‘it works!’ The mission of the foundation has always been to see this treatment reach human trials, and this brings us closer to fulfilling that mission.”
The complicated and intricate process of obtaining FDA approval is often difficult for the layperson to understand. “The holding company that holds all of the intellectual property (IP) for this was called ThermMed. They recently finished negotiations with a new company that will be taking over that IP. The new company will help support the research, but they are also very goal directed at getting in front of the FDA,” explained Dr. Curley. “We hope to have a meeting with the FDA in early 2014 to discuss the necessary steps in order to get to human trials.”
“As a foundation, we do not perform the research; we fund the research and report the outcomes,” shares Neidig. “This always leads to the million dollar question about when human trials will begin.” With a sense of surety, Dr. Curley declares, “our best case scenario is we could be in human trials by early 2015 – so a little more than a year from now. That’s a best case scenario. They (FDA) could come back and ask for several other large studies and it could be later than that. But that would be the earliest I would foresee.”
Dr. Curley made a promise to John Kanzius that he would see to it that human clinical trials took place. “I am going to keep that promise,” says Curley. “And part of that commitment is specifically to John’s hometowns of Erie and Sanibel who have been so supportive of our research.” Curley reiterates that as long as he is leading the project, these two communities will be proposed sites for Phase II human clinical trials to prove efficacy of the treatment.
About the Kanzius Cancer Research Foundation
Kanzius Cancer Research Foundation is a 501(c)(3) non‐profit organization with a mission to create national and global awareness of the potentials of the Kanzius Noninvasive Radiowave Cancer Treatment, and to help accelerate the speed at which this research progresses through human trials. The goal of the Kanzius Foundation is to raise money to support ongoing research grants. Pancreatic, liver and colorectal cancers in test subjects are undergoing extensive research in Houston and Pittsburgh; additional, ongoing studies are currently focused on breast, leukemic, lung, melanomic, osteocarcenomic and prostate cancers. For more information about the Kanzius research, visit www.Kanzius.org.